Dr. Jean-François Martini has biotech and pharma industry experience in preclinical pharmacology and clinical translational sciences and is author/coauthor of over 50 scientific publications. He is currently Executive Director, Translational Oncology, Global Product Development-Oncology and has been at Pfizer, in La Jolla, California, for the past 10 years. He was previously Sr. Director, Translational Medicine, at Exelixis, South San Francisco, California, where he contributed to the approval of cobimetinib and cabozantinib, and to projects such as the alliance with Sanofi for the PI3K programs and out-licensing of esaxerenone to Daiichi Sankyo.

He completed his postdoctoral training at University of California, San Francisco where he studied the antiangiogenic properties of fragments of Prolactin and Growth Hormone, after obtaining a PhD in Biochemistry (Molecular and Cellular Endocrinology) from University Paris VI, France. At Pfizer, he currently leads and/or supports the diagnostics and translational strategies for the cell cycle modulators (CDK inhibitors); the Renal Cell Cancer franchise (sunitinib, axitinib and checkpoint inhibitor combinations); the Lung Cancer franchise (lorlatinib, etc) and Colorectal cancer (encorafenib; etc). He is also the diagnostics lead for the rare diseases assets (Hemophilia A and B, and Duchenne muscular dystrophy gene therapies). He also leads the cross functional efforts in the area of liquid biopsy/cfDNA (represents Pfizer as part of Blood Profiling Atlas-Cancer; Friends of Cancer Research) and is the Pfizer board of director representative for the WIN consortium.